| pubmed-article:2295116 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2295116 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2295116 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:2295116 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:2295116 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:2295116 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2295116 | pubmed:dateCreated | 1990-2-9 | lld:pubmed |
| pubmed-article:2295116 | pubmed:abstractText | Oxaliplatin, or trans-1-diaminocyclohexane-platinum, was tested in a phase I study. A total of 44 patients received 116 courses with dose escalation from 45 to 200 mg/m2. Neither renal nor hematologic toxicities were observed at doses up to 200 mg/m2. Gastrointestinal toxicity was practically constant and often of grade 3-4 on the WHO scale (53% of patients). The dose-limiting toxicity was a peculiar sensory neuropathy; the first neurologic phenomena appeared at a dose of 135 mg/m2 and continued thereafter, occurring after 75% of the courses with mild to moderate intensity (WHO grade 1-2 after 67% of the courses). Neurotoxicity was cumulative and six patients developed grade 3 disabling neuropathy after a cumulative dose of 500 mg/m2, with walking and handwriting difficulties being slowly regressive in three cases. A peculiar symptom was the influence of temperature, with exacerbation of parethesias when patients touched cold surfaces. Nerve-conduction studies carried out in six cases showed a predominantly sensory neuropathy with axonal degeneration. No other toxicities were observed, although audiograms were not systematically done. We observed four partial responses that lasted 6-13 months in patients with oesophageal (2 cases), lung (1), and urothelial cancer (1); two of these patients had been pretreated with cisplatin. Since neurologic side effects occur very frequently and may produce a long-lasting sensory neuropathy, for phase II studies we recommend a starting dose of 135 mg/m2, with a careful neurologic survey. | lld:pubmed |
| pubmed-article:2295116 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2295116 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2295116 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2295116 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2295116 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2295116 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2295116 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2295116 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:2295116 | pubmed:author | pubmed-author:MignonFF | lld:pubmed |
| pubmed-article:2295116 | pubmed:author | pubmed-author:MartyMM | lld:pubmed |
| pubmed-article:2295116 | pubmed:author | pubmed-author:FermiGG | lld:pubmed |
| pubmed-article:2295116 | pubmed:author | pubmed-author:CalvoFF | lld:pubmed |
| pubmed-article:2295116 | pubmed:author | pubmed-author:ExtraJ MJM | lld:pubmed |
| pubmed-article:2295116 | pubmed:author | pubmed-author:EspieMM | lld:pubmed |
| pubmed-article:2295116 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2295116 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:2295116 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2295116 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2295116 | pubmed:pagination | 299-303 | lld:pubmed |
| pubmed-article:2295116 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:meshHeading | pubmed-meshheading:2295116-... | lld:pubmed |
| pubmed-article:2295116 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2295116 | pubmed:articleTitle | Phase I study of oxaliplatin in patients with advanced cancer. | lld:pubmed |
| pubmed-article:2295116 | pubmed:affiliation | Service d'Oncologie Médicale, l'Hôpital Saint Louis, Paris, France. | lld:pubmed |
| pubmed-article:2295116 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295116 | lld:pubmed |
